This Article Full Text Full Text (PDF) All Versions of this Article: 35/9/2145    most recent 01.STR.0000135773.24116.18v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Homma, S. Search for Related Content PubMed PubMed Citation Articles by Homma, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID WARFARIN Medline Plus Health Information Blood Thinners Related Collections Echocardiography Anticoagulants Antiplatelets

(Stroke. 2004;35:2145.)
© 2004 American Heart Association, Inc.

Original Contributions

Age As a Determinant of Adverse Events in Medically Treated Cryptogenic Stroke Patients With Patent Foramen Ovale

Shunichi Homma, MD; Marco R. DiTullio, MD; Ralph L. Sacco, MD, MS; Robert R. Sciacca, EngScD J.P. Mohr, MD for PICSS Investigators

From the Department of Medicine (S.H., M.R.D., R.R.S.) and the Neurological Institute (R.L.S., J.P.M.), Columbia University, New York, NY.

Correspondence to Dr Shunichi Homma, Division of Cardiology, Columbia University, College of Physicians & Surgeons, 630 West 168th Street, New York, NY 10032. E-mail sh23{at}columbia.edu

Background and Purpose— Patent foramen ovale (PFO) is associated with cryptogenic stroke. There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO. The purpose of this retrospective analysis from PFO in Cryptogenic Stroke Study (PICSS) database was to assess the effect of age on the risk of adverse events in medically treated cryptogenic stroke patients with PFO.

Methods— 250 cryptogenic stroke patients from PICSS were followed-up for 24 months, with death and recurrent ischemic stroke as primary endpoints. Hazard ratios were calculated for determination of relative risk in cryptogenic stroke patients with and without PFO in 3 age groups (younger than 55, 55 to 64, and 65 years or older).

Results— Among the 2 younger age groups, the presence of PFO did not significantly affect the risk of adverse events (P=0.15; hazard ratio=0.21; 95% CI, 0.02 to 1.78; 2-year event rates, 2.0% versus 9.3%; and P=0.70; hazard ratio=0.72; 95% CI, 0.14 to 3.73; 2-year event rates, 10.0% versus 13.9%). However, in those aged 65 years or older, the risk of adverse events was significantly higher in the patients with PFO (P=0.01; hazard ratio=3.21; 95% CI, 1.33 to 7.75; 2-year event rates 37.9% versus 14.5%).

Conclusions— In this exploratory analysis, the presence of PFO in the younger cryptogenic stroke patients did not increase the risk of adverse events. However, in the older patients, PFO significantly increased the risk of adverse events.

Key Words: aspirin • echocardiography • stoke • warfarin

This article has been cited by other articles:

				P. T. O'Gara, S. R. Messe, E. M. Tuzcu, G. Catha, and J. C. Ring Percutaneous Device Closure of Patent Foramen Ovale for Secondary Stroke Prevention: A Call for Completion of Randomized Clinical Trials A Science Advisory From the American Heart Association/American Stroke Association and the American College of Cardiology Foundation The American Academy of Neurology affirms the value of this science advisory J. Am. Coll. Cardiol., May 26, 2009; 53(21): 2014 - 2018. [Abstract] [Full Text] [PDF]

				P. T. O'Gara, S. R. Messe, E. M. Tuzcu, G. Catha, and J. C. Ring Percutaneous Device Closure of Patent Foramen Ovale for Secondary Stroke Prevention: A Call for Completion of Randomized Clinical Trials: A Science Advisory From the American Heart Association/American Stroke Association and the American College of Cardiology Foundation The American Academy of Neurology affirms the value of this science advisory. Circulation, May 26, 2009; 119(20): 2743 - 2747. [Abstract] [Full Text] [PDF]

				B. Meier Stroke and migraine: a cardiologist's headache Heart, April 1, 2009; 95(7): 595 - 602. [Full Text] [PDF]

				S. R. Messe and S. E. Kasner Patent Foramen Ovale in Cryptogenic Stroke: Not to Close Circulation, November 4, 2008; 118(19): 1999 - 2004. [Full Text] [PDF]

				N U Weir An update on cardioembolic stroke Postgrad. Med. J., March 1, 2008; 84(989): 133 - 142. [Abstract] [Full Text] [PDF]

				M. Handke, A. Harloff, M. Olschewski, A. Hetzel, and A. Geibel Patent Foramen Ovale and Cryptogenic Stroke in Older Patients N. Engl. J. Med., November 29, 2007; 357(22): 2262 - 2268. [Abstract] [Full Text] [PDF]

				B. Meier Patent Foramen Ovale, Guilty But Only as a Gang Member and for a Lesser Crime J. Am. Coll. Cardiol., January 17, 2006; 47(2): 446 - 448. [Full Text] [PDF]

				J. R. Kizer and R. B. Devereux Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N. Engl. J. Med., December 1, 2005; 353(22): 2361 - 2372. [Full Text] [PDF]

				S. Homma and R. L. Sacco Patent Foramen Ovale and Stroke Circulation, August 16, 2005; 112(7): 1063 - 1072. [Full Text] [PDF]